HBIO Quote, Financials, Valuation and Earnings

Azenta has a net margin of -21.86% compared to Harvard Bioscience's net margin of -2.93%. Harvard Bioscience's return on equity of -20.42% beat Azenta's return on equity of -7.49%.

Harvard Bioscience has a consensus price target of --, signalling upside risk potential of 196.91%. On the other hand Azenta has an analysts' consensus of -- which suggests that it could grow by 12.24%. Given that Harvard Bioscience has higher upside potential than Azenta, analysts believe Harvard Bioscience is more attractive than Azenta.

Harvard Bioscience has a beta of 1.272, which suggesting that the stock is 27.217% more volatile than S&P 500. In comparison Azenta has a beta of 1.493, suggesting its more volatile than the S&P 500 by 49.318%.

Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Harvard Bioscience quarterly revenues are $22M, which are smaller than Azenta quarterly revenues of $170.1M. Harvard Bioscience's net income of -$4.8M is higher than Azenta's net income of -$5M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.93x versus 4.09x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of -21.86% compared to Harvard Bioscience's net margin of -728.57%. Harvard Bioscience's return on equity of -20.42% beat Bionano Genomics's return on equity of -158.95%.

Harvard Bioscience has a consensus price target of --, signalling upside risk potential of 196.91%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 396.77%. Given that Bionano Genomics has higher upside potential than Harvard Bioscience, analysts believe Bionano Genomics is more attractive than Harvard Bioscience.

Harvard Bioscience has a beta of 1.272, which suggesting that the stock is 27.217% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.944%.

Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Harvard Bioscience quarterly revenues are $22M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Harvard Bioscience's net income of -$4.8M is higher than Bionano Genomics's net income of -$44.2M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.93x versus 0.28x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -21.86% compared to Harvard Bioscience's net margin of 4.73%. Harvard Bioscience's return on equity of -20.42% beat Bruker's return on equity of 19.61%.

Harvard Bioscience has a consensus price target of --, signalling upside risk potential of 196.91%. On the other hand Bruker has an analysts' consensus of $74.01 which suggests that it could grow by 29.77%. Given that Harvard Bioscience has higher upside potential than Bruker, analysts believe Harvard Bioscience is more attractive than Bruker.

Harvard Bioscience has a beta of 1.272, which suggesting that the stock is 27.217% more volatile than S&P 500. In comparison Bruker has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.733%.

Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.35% to investors and pays a quarterly dividend of $0.05 per share. Harvard Bioscience pays -- of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Harvard Bioscience quarterly revenues are $22M, which are smaller than Bruker quarterly revenues of $864.4M. Harvard Bioscience's net income of -$4.8M is lower than Bruker's net income of $40.9M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Bruker's PE ratio is 27.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.93x versus 2.60x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Singular Genomics Systems has a net margin of -21.86% compared to Harvard Bioscience's net margin of -4136.7%. Harvard Bioscience's return on equity of -20.42% beat Singular Genomics Systems's return on equity of -54.24%.

Harvard Bioscience has a consensus price target of --, signalling upside risk potential of 196.91%. On the other hand Singular Genomics Systems has an analysts' consensus of -- which suggests that it could fall by -36.8%. Given that Harvard Bioscience has higher upside potential than Singular Genomics Systems, analysts believe Harvard Bioscience is more attractive than Singular Genomics Systems.

Harvard Bioscience has a beta of 1.272, which suggesting that the stock is 27.217% more volatile than S&P 500. In comparison Singular Genomics Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Harvard Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Singular Genomics Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience pays -- of its earnings as a dividend. Singular Genomics Systems pays out -- of its earnings as a dividend.

Harvard Bioscience quarterly revenues are $22M, which are larger than Singular Genomics Systems quarterly revenues of $406K. Harvard Bioscience's net income of -$4.8M is higher than Singular Genomics Systems's net income of -$16.8M. Notably, Harvard Bioscience's price-to-earnings ratio is -- while Singular Genomics Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience is 0.93x versus 18.34x for Singular Genomics Systems. Usually stocks with elevated PS ratios are considered overvalued.